Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data

R. Crea, DVM, MSc, Jui-Fu Huang, Naghmana Bajwa, Alessandro Gringeri, MD PhD

Blood (2017) 130 (Supplement 1): 3686.

https://doi.org/10.1182/blood.V130.Suppl_1.3686.3686

Published: 2017

Journal Articles

Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis

Matteo Rota, Paolo A Cortesi, Roberto Crea, DVM, MSc, Alessandro Gringeri, MD PhD, Lorenzo G Mantovani

Blood (2017) 130 (Supplement 1): 1077.

https://doi.org/10.1182/blood.V130.Suppl_1.1077.1077

Published: 2017

Journal Articles

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

Roberto Crea, DVM, MSc, Aaron Novack, Armin J Reininger, Justine Kennedy, Sandra Raff, Alessandro Gringeri, MD MSc, Naghmana Bajwa

Blood (2016) 128 (22): 5031.

https://doi.org/10.1182/blood.V128.22.5031.5031

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients

Johannes Oldenburg, Prof, Dimitrios Tsakiris, Prof, Cedric R. Hermans, MD PhD MRCP, RI Liesner, MD FRCP, FRCPath, MA, MBBChir, Kate Khair, Maria Gabriella Mazzucconi, Prof, Katharina N Steinitz-Trost, PhD, Gerald Spotts, PhD, Armin J Reininger, Prof, Alessandro Gringeri, MD MSc

Blood (2016) 128 (22): 3786.

https://doi.org/10.1182/blood.V128.22.3786.3786

Published: 2016

Journal Articles

Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?

Lorenzo G. Mantovani, Matteo Rota, Paolo Cortesi, Katharina Steinitz, Armin Reininger, Alessandro Gringeri

Blood (2015) 126 (23): 289.

https://doi.org/10.1182/blood.V126.23.289.289

Published: 2015

Journal Articles

Validation of the rAHF-PFM PK Guided Dose Calculator Medical Device Using an Unrelated Clinical Dataset

Katharina Nora Steinitz, PhD, Gerald Spotts, PhD, Alexandra Loew-Baselli, PhD, Myungshin Oh, PhD, Mark Penny, Alessandro Gringeri, MD, Armin J Reininger, MD

Blood (2014) 124 (21): 1500.

https://doi.org/10.1182/blood.V124.21.1500.1500

Published: 2014

Journal Articles

Joint Disease and the Potential for Improved Joint Health in Inhibitor Patients Who Have a Good Response to aPCC Prophylaxis: Data From the Profeiba Study

Cindy A. Leissinger, MD, Alessandro Gringeri, MD, Leonard A. Valentino, MD, Paolo A Cortesi, MSc

Blood (2012) 120 (21): 3374.

https://doi.org/10.1182/blood.V120.21.3374.3374

Published: 2012

Journal Articles

Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: Results From the Pro-FEIBA Study,

Alessandro Gringeri, MD, Cindy A. Leissinger, MD, Paolo Cortesi, PharmD, Hyejin Jo, MS, Lorenzo Mantovani, DSc

Blood (2011) 118 (21): 4187.

https://doi.org/10.1182/blood.V118.21.4187.4187

Published: 2011

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Alessandro Gringeri, MD, MSc, Kathelijn Fischer, MD, PhD, MSc, Anastasia Karafoulidou, MD, Robert Klamroth, MD, Maria Fernanda Lopez, MD, Maria Elisa Mancuso, MD

Blood (2009) 114 (22): 1294.

https://doi.org/10.1182/blood.V114.22.1294.1294

Published: 2009

Journal Articles

Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted

Alessandro Gringeri, Pier Mannuccio Mannucci

Blood (2007) 110 (8): 3084.

https://doi.org/10.1182/blood-2007-06-095166

Published: 2007

Journal Articles

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Jan Astermark, Sharyne M. Donfield, Donna M. DiMichele, Alessandro Gringeri, Steven A. Gilbert, Jennifer Waters, Erik Berntorp, for the FENOC Study Group

Blood (2006) 109 (2): 546–551.

https://doi.org/10.1182/blood-2006-04-017988

Published: 2006

Journal Articles

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Erik Berntorp, MD, PhD, Sharyne Donfield, PhD, Jennifer Waters, JD, Eva Mattson, RN, Donna DiMichele, MD, Alessandro Gringeri, MD, PhD, Jan Astermark, MD, PhD

Blood (2005) 106 (11): 324.

https://doi.org/10.1182/blood.V106.11.324.324

Published: 2005

Journal Articles

Development and Pilot testing of a Disease-Specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL).

Sylvia v. Mackensen, PhD, Alessandro Gringeri, MD, Haem-A-QoL Study Group

Blood (2004) 104 (11): 2214.

https://doi.org/10.1182/blood.V104.11.2214.2214

Published: 2004

Journal Articles

Patient Preferences for Treatment Products in Hemophilia: A Conjoint Analysis (Conan Study Group).

Alessandro Gringeri, MD, MSc, Piermannuccio Mannucci, MD, Mara Monzini, PharmD, Luciana Scalone, PharmD, Lorenzo Mantovani, MSc, DSc

Blood (2004) 104 (11): 2203.

https://doi.org/10.1182/blood.V104.11.2203.2203

Published: 2004

Journal Articles

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

Alessandro Gringeri, Lorenzo G. Mantovani, Luciana Scalone, Pier Mannuccio Mannucci, the COCIS Study Group

Blood (2003) 102 (7): 2358–2363.

https://doi.org/10.1182/blood-2003-03-0941

Published: 2003

Journal Articles

Hemophilia and Nonprogressing Human Immunodeficiency Virus Type 1 Infection

Elisa Vicenzi, Patrizia Bagnarelli, Elena Santagostino, Silvia Ghezzi, Massimo Alfano, Marina S. Sinnone, Giovanna Fabio, Lucia Turchetto, Gianluca Moretti, Adriano Lazzarin, Alberto Mantovani, Pier Mannuccio Mannucci, Massimo Clementi, Alessandro Gringeri, Guido Poli

Blood (1997) 89 (1): 191–200.

https://doi.org/10.1182/blood.V89.1.191

Published: 1997

NARROW

United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data

Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients

Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?

Validation of the rAHF-PFM PK Guided Dose Calculator Medical Device Using an Unrelated Clinical Dataset

Joint Disease and the Potential for Improved Joint Health in Inhibitor Patients Who Have a Good Response to aPCC Prophylaxis: Data From the Profeiba Study

Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: Results From the Pro-FEIBA Study,

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Development and Pilot testing of a Disease-Specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL).

Patient Preferences for Treatment Products in Hemophilia: A Conjoint Analysis (Conan Study Group).

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

Hemophilia and Nonprogressing Human Immunodeficiency Virus Type 1 Infection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only